Adis Drug Reviews
The Adis Drug Review program provides readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas. Adis Drug Reviews are single-agent, narrative reviews, written by the scientific editorial staff of Springer Nature using a tried and tested, meticulous approach, and then independently peer reviewed by international experts. These peer reviewers are clearly identified on the final published article for our Drug Evaluations, Q&As and Biosimilar Briefs, a degree of transparency that serves to underline the trusted reputation of this long-running program. For more information on our article types and processes, please read below:
Adis Drug Evaluations
Adis Drug Evaluations provide a definitive review of the important pharmacological properties, clinical efficacy and tolerability of an agent. They critically evaluate the most important data on new or established agents and define their clinical potential or most appropriate place in therapy.
AdisInsight Reports briefly review the important pharmacological properties, clinical efficacy and tolerability of a newly approved agent. These reports are based on drug profile information from AdisInsight (a proprietary Springer Nature database that tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond) and are published shortly after the drug receives approval in its first indication in any market.
Adis Drug Q&As
Adis Drug Q&As focus on the practical use of drugs in the clinical setting and are a succinct, evidence-based review of pharmacological properties, efficacy, tolerability and current clinical use.
Adis Biosimilar Briefs
Adis Biosimilar Briefs provide a succinct, evidence-based overview of the clinically relevant properties of a new biosimilar product (including comparisons with the reference biologic agent) soon after approval in a major market.
Selection of Agents
The selection of drugs to be reviewed is determined solely by Springer Nature scientific editorial staff. Drugs are included in the program based on inherent interest, appearance of early findings of clinical interest or of market launches, increasing patterns of use in major world markets and adequacy of supporting data to allow a critical appraisal. Publication is timed to coincide with reader interest and the need for an objective assessment of data.
Published medical literature identified using PUBMED, MEDLINE and EMBASE (and including conference abstracts and symposia proceedings) are the core sources for each review. The drug manufacturer is approached to identify and/or provide any additional key data, including significant unpublished contributory data. Although Adis journals are published in English, important non-English language papers are identified and translated as part of the collation process.
Springer Nature scientific editorial staff have full control over all aspects of the writing process, including decisions related to content of Adis Drug Reviews. Articles have a clinical perspective, with clinically relevant findings receiving the most emphasis. No external funding is received for the preparation of these reviews.
Each study included in an Adis Drug Evaluation is critically analysed to establish the appropriateness of its conclusions, based on its design. Well-designed, published trials generally receive the most consideration. However, unpublished studies and recent abstracts are considered suitable for inclusion where they clearly stand up to critical scrutiny and add an important element of information to the review. If data are not available or are insufficient to describe important properties of the drug under review, this is highlighted and implications are discussed.
Adis Drug Reviews undergo extensive internal (by experienced Springer Nature scientific editorial staff) and external (by international specialists with demonstrated knowledge of the therapeutic area) peer review during article development. During peer review, the drug manufacturer is offered an opportunity to comment on the technical accuracy of the manuscript. Changes resulting from comments received are made on the basis of scientific and editorial merit and are at the discretion of Springer Nature scientific editorial staff.
For more information on this program, please contact our publishing team.